Your English writing platform
Discover LudwigSuggestions(1)
Exact(34)
Other secondary endpoints of clinical cure in the ITT and CE populations, various ME population subgroups, and per-baseline pathogen in the ME population were analyzed using a 95% CI calculated by the Wilson score methodology.
Subjects with confirmed baseline isolates were included in the microbiologic-modified ITT (m-mITT) and microbiologically evaluable (ME) population, respectively.
MRSA: methicillin-resistant Staphylococcus aureus Pretherapy in vitro activity against baseline isolates for tigecycline and levofloxacin for the ME population are outlined in Table 5.
The microbiologically evaluable (ME) population consisted of CE patients who had a gram-positive respiratory pathogen recovered from baseline respiratory specimens or blood cultures.
A total of 14 tigecycline- and 27 imipenem/cilastatin-treated patients in the ME population had a positive pretherapy blood culture.
For the ME population, clinical cure rates were 80.6% for tigecycline and 82.4% for imipenem/cilastatin (95% CI -9.0, 5.4; Table 2).
Similar(26)
Although this analysis revealed that MP cells are more similar to transient ME populations than they are to other cell populations examined, they are also distinct from ME cells.
The primary efficacy endpoints were clinical response at the TOC visit for the m-mITT and ME populations.
Three primary populations of patients were assessed for safety, clinical, and bacteriologic outcomes; the modified intent-to-treat (mITT), microbiologic modified ITT m-mITTT), and the microbiologically evaluable (ME) populations.
Twenty-four patients (12 in each treatment group) were considered to have had inadequate source control and were excluded from the CE and ME populations.
Non-aligned markers (placed on the fictitious chromosome N) were 28.1 % for PV and 24.5 % for Me populations.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com